For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).<br>IC50 Value:<br>Target: NMDA receptor<br>in vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitiveNMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1].<br>in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4].<br></p>
Catalog Number | I002276 |
CAS Number | 174575-17-8 |
Synonyms | 2-amino-3-(2/’-chloro-5-(phosphonomethyl)-[1,1/’-biphenyl]-3-yl)propanoic acid |
Molecular Formula | C16H17ClNO5P |
Purity | ≥95% |
Target | NMDA Receptor |
Solubility | DMSO: ≤ 8.57 mg/mL |
Storage | Store at -20°C |
Reference | <p style=/line-height:25px/> |